Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer’s disease: a target trial emulation
- DOI
- 10.26187/deakin.34949362
- Published
- 2026
- Container
- Not recorded
- Publisher
- Deakin University
- Open access
- yes
Credibility signals
limited evidence Score 47/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- supportingPublication license: A publication license was supplied: https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode. Presence improves reuse transparency, not research validity.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.26187/deakin.34949362,
title = {Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer’s disease: a target trial emulation},
author = {Chuo-Yu Lee and Chih-Wei Hsu and Ping-Tao Tseng and Yi-Ya Fang and Brendon Stubbs and Trevor Thompson and Andre Carvalho and Yu-Hsuan Lin and Yu-Chen Kao and Fu-Chi Yang and Tien-Wei Hsu and Chih-Sung Liang},
year = {2026},
doi = {10.26187/deakin.34949362},
url = {https://doi.org/10.26187/deakin.34949362}
}RIS
TY - JOUR TI - Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer’s disease: a target trial emulation AU - Chuo-Yu Lee AU - Chih-Wei Hsu AU - Ping-Tao Tseng AU - Yi-Ya Fang AU - Brendon Stubbs AU - Trevor Thompson AU - Andre Carvalho AU - Yu-Hsuan Lin AU - Yu-Chen Kao AU - Fu-Chi Yang AU - Tien-Wei Hsu AU - Chih-Sung Liang PY - 2026 DO - 10.26187/deakin.34949362 UR - https://doi.org/10.26187/deakin.34949362 ER -
APA
Lee, C., Hsu, C., Tseng, P., Fang, Y., Stubbs, B., Thompson, T., Carvalho, A., Lin, Y., Kao, Y., Yang, F., Hsu, T., & Liang, C. (2026). Real-world effectiveness of monoclonal antibody lecanemab versus acetylcholinesterase inhibitors in Alzheimer’s disease: a target trial emulation. https://doi.org/10.26187/deakin.34949362
Source records
- datacite · retrieved 2026-11-10T20:15:01.316Z